Realtime | Geld | Brief | Zeit |
---|---|---|---|
24,050 | 25,050 | 02.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.07. | La Bastide: A Taste Of Provence, One Hour From New York City | 2 | Forbes | ||
30.06. | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 501 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
09.06. | BASTIDE: Disposal of CICADUM and MEDSOFT | 421 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
05.06. | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 402 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
04.06. | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 383 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
15.05. | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 410 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
19.03. | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 524 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen | |
13.02. | BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed | 403 | Actusnews Wire | Caissargues, February 13, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
08.01. | BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS | 342 | Actusnews Wire | Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British... ► Artikel lesen | |
14.11.24 | BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed | 418 | Actusnews Wire | Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024.
In... ► Artikel lesen | |
04.11.24 | BASTIDE: 2024-2025 financial calendar | 326 | Actusnews Wire | Caissargues, November 4, 2024
Events
Dates*
2024-2025 Q1 Revenue
Thursday November 14, 2024
2024-2025 H1 Revenue
Thursday February 13, 2025
2024-2025 H1 Results
Wednesday... ► Artikel lesen | |
23.10.24 | BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25 | 335 | Actusnews Wire | Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ANSELL | 19,300 | 0,00 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
AMBEA | 11,250 | -0,27 % | Ambea AB: Ambea's interim report April - June 2025 | strong>Higher growth rate and earnings
CEO comments:
We reported a strong trend during the quarter, with clear growth in sales and earnings. A significant part of this growth was driven by Validia... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 41,700 | -5,31 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,260 | -3,02 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS | 46,500 | -0,45 % | Fresenius: Analysten heben Kursziel kräftig an und schüren neue Fantasie für Gesundheitsaktie | Fresenius erhält von der UBS ein deutlich höheres Kursziel, da Analysten dem Gesundheitskonzern neue Wachstumschancen zutrauen. Die Empfehlung zum Kauf bleibt bestehen, während Experten weiteres Aufwärtspotenzial... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 23,880 | +0,80 % | BrightSpring Health Services, Inc. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Guidance | LOUISVILLE, Ky., May 02, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
PROGYNY | 23,410 | 0,00 % | Progyny, Inc. Announces Second Quarter 2025 Results | Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance... ► Artikel lesen | |
GERRESHEIMER | 43,500 | -3,63 % | Cancom, Friedrich Vorwerk, Gerresheimer, GFT, Hugo Boss, Wacker Chemie - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 39,560 | 0,00 % | Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts | ||
LIFESTANCE HEALTH GROUP | 5,630 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Second Quarter 2025 Results | SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
ATRICURE | 36,290 | 0,00 % | AtriCure, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
ALIGNMENT HEALTHCARE | 16,640 | 0,00 % | Analyst Favors Cigna, Alignment Healthcare, Cautious On Peers | ||
CARL ZEISS MEDITEC | 43,000 | -3,50 % | Wachstumsschmerz, Durchbruch und Entlassungen - Carl Zeiss Meditec, MiMedia Holdings, Nio | Die deutsche Automobilindustrie ist seit drei Jahren in einer tiefen Krise. Überkapazitäten belasten die Konzerne und die Verkaufszahlen im wichtigsten Absatzmarkt China brachen um bis zu 50 % im Vergleich... ► Artikel lesen | |
AVEANNA HEALTHCARE | 8,240 | +3,00 % | Moody's stuft Rating für Aveanna Healthcare auf B3 hoch - Ausblick stabil | ||
ADAPTHEALTH | 9,150 | 0,00 % | AdaptHealth Corp. - 10-Q, Quarterly Report |